733
edits
Secretariat (talk | contribs) No edit summary |
No edit summary |
||
(3 intermediate revisions by the same user not shown) | |||
Line 1: | Line 1: | ||
{| class="wikitable" border="1" | {| class="wikitable" border="1" | ||
|- | |- | ||
! colspan="6" | | ! colspan="6" | Overview of the Major Randomized Controlled Clinical Trials of ICD Therapy for Primary Prevention of SCD in Ischemic Cardiomyopathy<cite>Passman</cite> | ||
|- | |- | ||
! Study | ! Study | ||
Line 12: | Line 10: | ||
! Main Finding | ! Main Finding | ||
|- | |- | ||
| MADIT I<cite>35</cite> | | '''MADIT I'''<cite>35</cite> | ||
| Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | | Prior MI, EF ≤35%, NSVT, inducible and nonsuppressible VT on EPS, NYHA class I–III | ||
| align="center" | 196 | | align="center" | 196 | ||
Line 20: | Line 18: | ||
mortality with ICD (''P''=0.009); absolute RR 23% | mortality with ICD (''P''=0.009); absolute RR 23% | ||
|- | |- | ||
| CABG-PATCH<cite>36</cite> | | '''CABG-PATCH'''<cite>36</cite> | ||
| EF <35%, abnormal SAECG, elective CABG | | EF <35%, abnormal SAECG, elective CABG | ||
| align="center" | 900 | | align="center" | 900 | ||
Line 28: | Line 26: | ||
|- | |- | ||
| MUSTT<cite>37</cite> | | '''MUSTT'''<cite>37</cite> | ||
| Prior MI, EF ≤40%, NSVT, inducible VT on EPS | | Prior MI, EF ≤40%, NSVT, inducible VT on EPS | ||
| align="center" | 704 | | align="center" | 704 | ||
Line 36: | Line 34: | ||
|- | |- | ||
| MADIT II<cite>39</cite> | | '''MADIT II'''<cite>39</cite> | ||
| Prior MI≤1 month, EF≤30%, NYHA class I–III | | Prior MI≤1 month, EF≤30%, NYHA class I–III | ||
| align="center" | 1232 | | align="center" | 1232 | ||
Line 44: | Line 42: | ||
|- | |- | ||
| DINAMIT<cite>38</cite> | | '''DINAMIT'''<cite>38</cite> | ||
| Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | | Recent (6–40 days) MI, EF≤35%, abnormal HRV or elevated average HR on 24-h Holter, NYHA class I–III | ||
| align="center" | 674 | | align="center" | 674 | ||
Line 52: | Line 50: | ||
|- | |- | ||
| SCD-HeFT<cite>34</cite> | | '''SCD-HeFT'''<cite>34</cite> | ||
| EF≤35%, (ischemic or nonischemic) NYHA class II–III | | EF≤35%, (ischemic or nonischemic) NYHA class II–III | ||
| align="center" | 2521 | | align="center" | 2521 | ||
Line 65: | Line 63: | ||
==References== | ==References== | ||
<biblio> | <biblio> | ||
#34 | #Passman pmid=17664385 | ||
#34 pmid=15659722 | |||
#35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940. | #35 Moss A, Hall W, Cannom D, Daubert J, Higgins S, Klein H, Levine J, Saksena S, Waldo A, Wilber D, Brown M, Heo M; Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. ''N Engl J Med.'' 1996;335:1933–1940. | ||
#36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575. | #36 Bigger J; Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. ''N Engl J Med.'' 1997;337:1569 –1575. |